ACCION ANTIMICROBIANA DE SALIVARICINA CRL 1328 PRODUCIDA POR LACTOBACILLUS SALIVARIUS DE ORIGEN VAGINAL

OCAÑA V.; SPONTON N.; VERA PINGITORE E.; NADER-MACIAS M.E.

Tucumán

Simposio; II SIMPOSIO INTERNACIONAL DE BACTERIAS LÁCTICAS - Primer encuentro de la Red Bal Argentina; 2006

  In order to design a probiotic for the restoration of the vaginal microflora, our work group have started studies to deeply know the microorganisms and the antimicrobial substances that they produce, considering their potential use in formulations for the urogenital tract. In previous works, salivaricin CRL1328 produced by L. salivarius CRL1328 isolated from the human vagina, was characterized. The objective of the present work was to know the antimicrobial spectrum of salivaricin CRL1328 and to evaluate the potential application of this substance in the antimicrobial therapy. Pathogenic microorganisms were isolated from clinical samples of patients assisted at Nuevo Hospital El Milagro (Salta, Argentina). The salivaricina CRL1328 activity was first assayed by the antibiotic susceptibility standard technique by using bacteriocin-embedded discs, in order to compare the results with those obtained for antibiotics. Due to the low activity of  salivaricin in discs compared with the activity obtained by the standard method for bacteriocins, a three-fold concentration was employed on discs. This last concentration allowed to easily detect inhibition halos when using type Enterococcus strain, even after two month of storage at room temperature and under refrigeration. Antimicrobial activity of the bacteriocin was detected against Enterococcus and Staphylococcus saprophyticus strains, while Klebsiella pneumoniae, Pseudomona aeruginosa, Streptococcus agalactiae and Proteus mirabilis were resistant. All the isolated Enterococcus strains were susceptible to salivaricin, ampicillin and vancomycin, while two vancomycin-resistant Enterococcus type strains were resistant to salivaricin. From thirteen S. saprophyticus strains, eight were susceptible to the bacteriocin, but no correlation was detected between their susceptibility or resistance to salivaricin, meticillin or vancomycin. The Minimal Inhibitory Concentration (CMI) of salivaricin was different for the S. saprophyticus studied strains.  The obtained results indicate that salivaricin CRL1328 could be employed in a pharmaceutical product to control Enterococcus sp. and S. saprophyticus infections.